Sandu Pharmaceuticals (524703) Q1 25/26 earnings summary

Executive summary

• Unaudited standalone financial results for the quarter ended June 30, 2025, were approved and reviewed with an unmodified auditor's opinion.

• No consolidation required as there are no subsidiary companies.

• 40th Annual General Meeting scheduled for September 30, 2025, via video conferencing.

• Proposal for continuation of material related party transactions with Sandu Brothers Private Limited to be placed before shareholders.

• CFO Shri Vijay Kajarekar's continuation beyond age 70 subject to shareholder approval.

Financial highlights

• Revenue from operations for Q1 FY26 was ₹1,669.90 lakhs, up from ₹1,406.92 lakhs in Q1 FY25.

• Net profit for the quarter was ₹22.33 lakhs, compared to ₹16.69 lakhs in the same quarter last year.

• Total comprehensive income for the quarter stood at ₹32.66 lakhs, up from ₹35.46 lakhs in Q1 FY25.

• Basic and diluted EPS for the quarter was ₹0.23, compared to ₹0.17 in Q1 FY25.

Outlook and guidance

• Directors Report, Management Discussion and Analysis, and Corporate Governance Report for FY25 were approved.

• Closure of Register of Members and Share Transfer Books set for September 23–30, 2025; record date for dividend eligibility is September 18, 2025.